Borbe H O, Metzenauer P, Szelenyi I
ASTA Pharma AG, Department of Biochemistry, Frankfurt/Main, F.R.G.
Eur J Pharmacol. 1991 Nov 19;205(1):105-7. doi: 10.1016/0014-2999(91)90779-p.
Naftopidil, a novel antihypertensive compound, possesses 5-HT1A agonistic properties in addition to being an alpha 1-adrenoceptor antagonist. The IC50 values for alpha 1-adrenoceptors (235 nmol/l) and for 5-HT1A receptors (108 nmol/l) lie in the same concentration range. The reduction in blood pressure of anesthetized cats by 8-OH-DPAT and urapidil was completely abolished by spiroxatrine, a 5-HT1A antagonist. However, the decreases in blood pressure induced by naftopidil were only partly antagonized by spiroxatrine.